HoloMD, a company specializing in an AI-powered Remote Therapeutic Monitoring (RTM) platform for psychiatry, has successfully completed a $1.6 million first close of its $3 million seed funding round.
The new capital will accelerate the development and expansion of Dr. Holo™, the company’s human-supervised AI companion designed to support psychiatrists and their patients between visits. Dr. Holo facilitates daily engagement, provides evidence-based interactions, and generates actionable clinical insights. The platform leverages 40 years of psychiatric expertise to enable providers to deliver high-quality care outside of traditional sessions, which is intended to improve patient outcomes, reduce clinician burnout, and create new revenue streams through RTM reimbursement.
Within 15 months, HoloMD completed Phase 1 of its platform rollout, progressing from concept to generating revenue and establishing its reimbursement model in clinical settings. Initial deployments have shown strong patient engagement, positive feedback from clinicians, and validated RTM billing with multiple commercial payers. This foundation positions HoloMD for expansion into additional practices and markets during its next growth phase.
Dr. Holo engages patients via daily check-ins and micro-interventions, then translates emotional, contextual, and behavioral data into concise, visit-ready insights for providers. Each interaction is reviewed by licensed clinicians to ensure safety, empathy, and accuracy, balancing scalable automation with human oversight. The platform structures these interactions to comply with RTM CPT codes, making previously uncompensated work eligible for reimbursement.
Bruce A. Kehr, MD, Founder and CEO of HoloMD, stated, “Built by psychiatrists for psychiatrists and PMHNPs, our mission is to extend healing beyond the clinic walls. Dr. Holo engages patients daily, identifies successes and challenges, and equips clinicians with actionable insights to improve diagnosis and treatment, while enabling care between visits that is eligible for reimbursement.” Jim Pearson, HoloMD’s Executive Chairman, added, “HoloMD sits at the intersection of better outcomes and better economics. By aligning eligible RTM reimbursement with continuous patient support, we have created a sustainable model designed to help clinicians improve outcomes while scaling care sustainably.”
Investment highlights include proven leadership from Executive Chairman Jim Pearson, who has overseen three prior healthcare exits totaling $450 million with companies such as Stryker and Hologic. The company is clinically founded, drawing on Dr. Bruce Kehr’s 40 years of psychiatric expertise from Potomac Psychiatry. Its reimbursement model is validated for RTM workflows by Medicare and commercial payers. The platform features human-supervised AI, combining scalable automation with clinician oversight. HoloMD also has intellectual property momentum, with a patent-pending platform and an expanding national pipeline.
HoloMD has developed a patent-pending AI-powered psychiatry platform that augments clinicians with continuous, human-supervised patient engagement and RTM-aligned workflows. This platform is designed to provide critical information to improve outcomes and reduce costs. Founded in July 2024, the company adheres to HIPAA and HITECH compliance standards, supports Medicare RTM billing, and currently holds seven provisional and one utility patent pending, along with three trademarks pending. The company plans to host a virtual investor presentation on Tuesday, November 11, 2025, at 12:00 p.m. ET.
